Cardio3 tests Europe's appetite for biotech IPOs

The big surge of biotech IPOs over the last few months has largely been restricted to the United States. But now a European biotech with a Phase III heart therapy in the clinic will see if it can get the mojo working on the continent. Belgium's Cardio3 BioSciences said today that it is plotting an IPO, but didn't spell out how much the company was planning to raise. Reuters reports that Belgium hasn't seen an IPO since Movetis went public four years ago. A couple of weeks ago Cardio3 said it raised $24 million from investors. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.